NCT02615847View on ClinicalTrials.gov

Clinical Trial to Study the Safety and Tolerability of Memantin Mepha® in Sickle Cell Disease Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

July 31, 2017

Conditions
Sickle Cell Disease
Interventions
DRUG

Memantinhydrochlorid

"Memantin Mepha® Lactabs (memantinehydrochlorid) will be provided as 5 mg, 10 mg, 15 mg and 20 mg tablets, packed in blister.~The study drug will be taken once a day per os, during 12 month."

Trial Locations (1)

8091

University Hospital Zürich, Zurich

All Listed Sponsors
lead

University of Zurich

OTHER

NCT02615847 - Clinical Trial to Study the Safety and Tolerability of Memantin Mepha® in Sickle Cell Disease Patients | Biotech Hunter | Biotech Hunter